Jeff Beck | Chief Development Officer New Business Update
BioCare team, we are off to a fabulous start to 2022 and that’s following a record year where we reached $1B in revenue! The first quarter is already in the books and it was another record breaker. At the close of 2021 the new business team added four new products which are really starting to pick up steam as we finish Q1. TEPEZZA, KRYSTEXXA, UPLIZNA and VYVGART had combined revenues of over $25MM! While we are happy with these additions, we are relentlessly pursuing a multitude of other opportunities in our new business pipeline. We have firm commitments to distribute four more new products in 2022 or early 2023, depending on when the manufacturers receive approval and launch.
Our strategy has remained consistent in our new business prospecting. The specific criteria the team looks for in new products are the following:
• Core, adjacent and new therapeutic areas per strategic plan o Hematology, Neurology, Immunology, Ophthalmology, Rheumatology, Biosimilars o Opportunistic especially with current partners and known entities with relationships • Drug Indications o Do we already have drugs with these indications? o If not, does our sales team have the knowledge and bandwidth? • Route of administration o IV & Sub-Q, are preferred for now, but we are open to other routes of administration
I will keep everyone apprised as new products come on board. Let’s keep the momentum going and have another record year!
JUNE PRIDE MONTH
8
Powered by FlippingBook